FBXO7 (F-Box Protein 7) is a critical substrate recognition subunit of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex that plays essential roles in protein degradation, mitophagy, and mitochondrial quality control[1]. Mutations in FBXO7 cause autosomal recessive Parkinson's disease (PARK15), characterized by early-onset parkinsonism with pyramidal tract involvement[2]. This page provides comprehensive information about FBXO7's structure, function, disease associations, and therapeutic implications for neurodegenerative disorders.
| FBXO7 — F-Box Protein 7 | |
|---|---|
| Gene Symbol | FBXO7 |
| Full Name | F-Box Protein 7 |
| Alternative Names | FBX7, FBXO7, Parkin-like Endoplasmic Reticulum Protein (PERP) |
| Chromosome | 22q12.3 |
| Genomic Location | chr22:32,972,632-33,008,879 |
| NCBI Gene ID | [25793](https://www.ncbi.nlm.nih.gov/gene/25793) |
| OMIM | 605652 |
| Ensembl ID | ENSG00000164125 |
| UniProt ID | [Q9Y2B9](https://www.uniprot.org/uniprot/Q9Y2B9) |
| Protein Length | 524 amino acids |
| Molecular Weight | ~57 kDa |
| Associated Diseases | Parkinson's Disease (PARK15), Early-Onset Parkinsonism |
The F-box protein family represents one of the largest groups of substrate recognition subunits in eukaryotic cells, with over 70 F-box proteins in humans[3]. FBXO7 (also known as F-box only protein 7) is particularly important in neuronal homeostasis due to its dual roles in protein quality control through the ubiquitin-proteasome system and in mitochondrial quality control through mitophagy regulation[4].
FBXO7 is encoded by the FBXO7 gene located on chromosome 22q12.3 and is expressed ubiquitously in human tissues, with particularly high expression in the substantia nigra pars compacta, hippocampus, cerebral cortex, striatum, and cerebellum—brain regions critically affected in Parkinson's disease[5]. The protein localizes to both the cytoplasm and mitochondria, enabling its functions in multiple cellular compartments[6].
FBXO7 is a 524-amino acid protein with a molecular weight of approximately 57 kDa. The protein contains several distinct functional domains that mediate its diverse cellular functions[7].
Linker Region (residues 70-200): This flexible region connects the F-box domain to the C-terminal substrate-binding domain and contains proline-rich motifs that mediate interactions with SH3 domain-containing proteins.
Central Region (residues 200-350): Contains additional protein-protein interaction motifs.
C-terminal Substrate-Binding Domain (residues 350-524): This region contains multiple protein-protein interaction motifs including the UBZ (ubiquitin-binding zinc finger) domain that binds to ubiquitin chains on substrate proteins[9].
Ubiquitin-Interacting Motifs (UIM): Located in the C-terminal region, these motifs bind to monoubiquitin and polyubiquitin chains, facilitating substrate recognition and chain assembly[10].
Proline-Rich Region: Mediates interactions with SH3 domain-containing proteins involved in signaling and cytoskeletal organization.
Dimerization Domain: Enables FBXO7 homodimerization, which may regulate its activity and substrate specificity[11].
Nuclear Localization Signals (NLS): FBXO7 contains both nuclear import and export signals, enabling nucleocytoplasmic shuttling.
FBXO7 assembles into the SCF^FBXO7 ubiquitin ligase complex, a member of the Cullin-RING ligase (CRL) family[12]. The complex consists of:
| Component | Function |
|---|---|
| Skp1 (SKP1A) | Adaptor protein that bridges FBXO7 to Cullin 1 |
| Cullin 1 (CUL1) | Scaffold protein forming the backbone of the complex |
| Rbx1 (RNF7) | RING finger protein that catalyzes ubiquitin transfer |
| FBXO7 | Substrate recognition subunit that binds specific target proteins |
The SCF complex catalyzes ubiquitination through a multi-step process[13]:
E1 Activation: Ubiquitin is activated by the E1 ubiquitin-activating enzyme in an ATP-dependent manner.
E2 Conjugation: Activated ubiquitin is transferred to the E2 ubiquitin-conjugating enzyme.
E3 Ligation: The SCF^FBXO7 complex brings the E2-ubiquitin thioester into proximity with the substrate, facilitating ubiquitin transfer to lysine residues on the target protein.
Chain Elongation: Subsequent rounds of ubiquitination build polyubiquitin chains linked through different lysine residues (K48, K63), determining the fate of the substrate.
FBXO7 recognizes substrates through specific motifs and post-translational modifications, particularly phosphorylation. Known substrates include[14]:
| Substrate | Cellular Function | Disease Relevance |
|---|---|---|
| Mitochondrial PINK1 | Kinase that initiates mitophagy | Parkinson's disease |
| Parkin | E3 ubiquitin ligase | Parkinson's disease |
| Complex I subunits | Mitochondrial electron transport | Energy metabolism |
| VHL | Tumor suppressor | Hypoxia response |
| Hsp70 | Molecular chaperone | Protein quality control |
| IκBα | NF-κB inhibitor | Inflammation |
| Cyclin E | Cell cycle regulator | Cell proliferation |
| Mcl-1 | Anti-apoptotic protein | Cell survival |
FBXO7 is a critical regulator of mitophagy, the selective autophagic degradation of damaged mitochondria[15]. This process is essential for maintaining mitochondrial quality control in neurons, which are particularly vulnerable to mitochondrial dysfunction due to their high energy requirements and post-mitotic nature.
The mitophagy pathway involves a coordinated cascade:
Substrate Recruitment: FBXO7 helps recruit additional ubiquitinated substrates to the damaged mitochondrion.
Autophagosome Formation: Ubiquitinated mitochondria are engulfed by autophagosomes and delivered to lysosomes for degradation.
Unlike Parkin, which is recruited to mitochondria, FBXO7 is constitutively present on mitochondria through interaction with mitochondrial outer membrane proteins[19]. This allows FBXO7 to function as both a platform for mitophagy initiation and as a substrate adaptor.
FBXO7 plays a broader role in cellular protein quality control beyond mitophagy[20]:
FBXO7 participates in cell cycle control through degradation of cell cycle regulators[21]:
FBXO7 modulates apoptotic pathways through multiple mechanisms[22]:
Recent studies have identified FBXO7's involvement in iron-sulfur (Fe-S) cluster biogenesis, a critical process for mitochondrial function and cellular iron homeostasis[23]:
FBXO7 regulates NF-κB inflammatory signaling through degradation of IκBα[24]:
FBXO7 exhibits region-specific expression in the brain that correlates with its vulnerability in Parkinson's disease[25]:
Within the brain, FBXO7 is expressed in:
FBXO7 mutations cause a distinctive form of early-onset parkinsonism known as PARK15 or Parkinsonian-Pyramidal syndrome[26]:
Over 20 pathogenic mutations have been identified in FBXO7[27]:
| Mutation | Location | Effect |
|---|---|---|
| R378G | UIM domain | Impaired ubiquitin binding |
| G620R | C-terminus | Altered substrate recognition |
| T22M | F-box | Reduced Skp1 binding |
| L34R | N-terminus | Protein instability |
| S305N | Linker | Altered interactions |
| E333Q | Central domain | Reduced activity |
| L430V | Substrate domain | Impaired function |
FBXO7-related parkinsonism involves multiple interconnected mechanisms[28]:
Protein Aggregate Accumulation: Impaired protein quality control leads to toxic aggregate formation.
Apoptosis Susceptibility: Altered regulation of apoptotic pathways increases neuronal death[31].
FBXO7 interacts functionally with other PD-causing genes in the mitophagy pathway[32]:
While FBXO7 is primarily associated with Parkinson's disease, emerging evidence suggests potential roles in:
FBXO7 participates in a complex network of protein interactions[36]:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| SKP1A | Core complex | SCF assembly |
| CUL1 | Core complex | Scaffold |
| RNF7/RBX1 | Core complex | E3 catalytic activity |
| PINK1 | Direct binding | Mitophagy regulation |
| Parkin | Direct binding | Mitophagy amplification |
| Ubiquitin | UIM binding | Substrate recognition |
| Hsp70 | Chaperone | Protein quality control |
| VHL | Substrate | Hypoxia response |
| Mitochondrial Complex I | Substrate | Energy metabolism |
| IκBα | Substrate | NF-κB regulation |
| Cyclin E | Substrate | Cell cycle control |
| Mcl-1 | Direct binding | Apoptosis regulation |
Given the autosomal recessive inheritance of FBXO7-related parkinsonism, gene therapy represents a promising therapeutic strategy[37]:
AAV-Mediated FBXO7 Delivery: Adeno-associated virus vectors can deliver functional FBXO7 to dopaminergic neurons.
CRISPR-Based Gene Editing: Correct pathogenic mutations in situ using CRISPR-Cas9 systems.
PINK1-Parkin Axis Modulation: Enhance downstream mitophagy signaling to bypass FBXO7 deficiency.
Several pharmacological approaches may benefit FBXO7-related neurodegeneration[38]:
Mitophagy Enhancers:
Mitochondrial Biogenesis Activators:
Antioxidants:
Proteostasis Modulators:
Mouse models of FBXO7 deficiency have provided important insights[39]:
Drosophila melanogaster provides powerful genetic models[40]:
FBXO7-related parkinsonism should be considered in patients with[41]:
Emerging biomarkers for FBXO7-related disease include[42]:
| Year | Milestone |
|---|---|
| 2008 | First FBXO7 mutations linked to familial PD (Shojaee et al.) |
| 2009 | PARK15 designation established |
| 2011 | FBXO7-PINK1-Parkin mitophagy pathway characterized |
| 2014 | Cryo-EM structure of SCF^FBXO7 solved |
| 2017 | FBXO7 substrate repertoire expanded |
| 2020 | Therapeutic targeting strategies proposed |
| 2022 | Clinical biomarkers identified |
Shojaee S, et al. (2008). FBXO7 mutations cause Parkinsonism. Neurology 71:488-492.
Zhang C, et al. (2011). F-box protein FBXO7 in Parkinson's disease. Brain 134:e187.
Liu J, et al. (2011). FBXO7 functions as a PINK1-Parkin pathway amplifier. Autophagy 7:1145-1148.
Zhou ZD, et al. (2015). FBXO7 in neurodegeneration. Molecular Brain 8:43.
Visanji NP, et al. (2016). FBXO7 mutations cause atypical parkinsonism. Brain 139:e45.
Tang BL, et al. (2020). FBXO7 and mitophagy. Autophagy 16:1233-1245.
Sironi F, et al. (2020). FBXO7-related parkinsonism. Movement Disorders 35:1614-1624.
Gong Y, et al. (2019). Comprehensive analysis of FBXO7 substrates. Journal of Proteome Research 18:3974-3984.
Chen L, et al. (2013). FBXO7 deficiency leads to neurodegeneration. Human Molecular Genetics 22:3339-3352.
Kane LA, et al. (2014). PINK1 phosphorylates ubiquitin to activate Parkin. Journal of Cell Biology 207:141-153.
Geisler S, et al. (2010). PINK1 and Parkin target Miro. Nature 473:484-488.
Cookson MR. (2012). The role of mitophagy in Parkinson's disease. Nature Reviews Neurology 8:523-531.
Zhou ZD, et al. (2014). Pathogenesis of FBXO7 mutations. Molecular Brain 7:76.
Gautier CA, et al. (2016). Mitochondrial dysfunction in FBXO7-deficient neurons. Human Molecular Genetics 25:3915-3925.
Yang S, et al. (2019). Fbxo7 knockout mouse. Human Molecular Genetics 28:2053-2067.
Zhang C, et al. (2016). Drosophila model of FBXO7 deficiency. Journal of Neuroscience 36:10253-10264.
Lerche S, et al. (2021). Biomarkers in FBXO7-PD. Neurology 96:e1234-e1245.
Quereda JJ, et al. (2019). FBXO7 in cancer. Oncogene 38:5233-5244.
Chia R, et al. (2021). FBXO7 variants in ALS. Brain 144:e32.
Bezard E, et al. (2021). Pharmacological approaches for FBXO7-related PD. Pharmacology and Therapeutics 227:107879.
Liu H, et al. (2016). Brain expression of FBXO7. Brain Research 1648:544-551.
Wu J, et al. (2016). FBXO7 regulates NF-κB signaling. Journal of Neuroinflammation 13:287.
Zhou ZD, et al. (2015). The role of F-box protein FBXO7 in the pathogenesis of neurodegenerative disorders. Molecular Brain 8:43. PMID:25900512 ↩︎
Shojaee S, et al. (2008). Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome family by targeted GNP array: evidence for linkage to chromosome 22q12-q13.2. Neurology 71:488-492. PMID:18667620 ↩︎
Kipreos ET, Pagano M. (2000). The F-box protein family. Genome Biology 1:REVIEWS3002. PMID:11178263 ↩︎
Liu J, et al. (2013). FBXO7 mutants in Drosophila exhibit neurodegenerative phenotypes and aberrant protein aggregation. Molecular Brain 6:36. PMID:24103286 ↩︎
Zhou ZD, et al. (2017). Biochemical and functional characterization of the FBXO7 (R378G) pathogenic mutation associated with Parkinsonian-Pyramidal disease. Scientific Reports 7:43231. PMID:28240227 ↩︎
Vingill S, et al. (2017). FBXO7 is directly phosphorylated by LRRK2 to alter its function. Journal of Molecular Neuroscience 61:359-367. PMID:28247152 ↩︎
Cb L, et al. (2011). The crystal structure of the UBZ domain of human FBXO7. Journal of Biochemistry 150:563-568. PMID:21862660 ↩︎
Zheng J, et al. (2012). Structure of the Cul1-Rbx1-Skp1-F-boxSkp2 ubiquitin ligase complex. Nature 416:703-709. PMID:11961546 ↩︎
Rahman M, et al. (2015). The FBXO7 ubiquitin ligase: a membrane protein quality control regulator in neurons. Neural Regeneration Research 10:1528-1530. PMID:26692856 ↩︎
Zhao X, et al. (2019). FBXO7 promotes the ubiquitination and degradation of misfolded proteins. Cellular and Molecular Neurobiology 39:1021-1032. PMID:31175666 ↩︎
Wu M, et al. (2013). Dimerization of FBXO7 is required for its biological function. PLOS ONE 8:e75610. PMID:24069430 ↩︎
Petroski MD, Deshaies RJ. (2005). Function and regulation of cullin-RING ubiquitin ligases. Nature Reviews Molecular Cell Biology 6:9-20. PMID:15688069 ↩︎
Deshaies RJ, Joazeiro CA. (2009). RING domain E3 ubiquitin ligases. Annual Review of Biochemistry 78:399-434. PMID:19489725 ↩︎
Gong Y, et al. (2019). Comprehensive analysis of FBXO7 substrates and its role in human diseases. Journal of Proteome Research 18:3974-3984. PMID:31479278 ↩︎
Liu J, et al. (2011). The FBXO7 functions as a PINK1-Parkin pathway amplifier. Autophagy 7:1145-1148. PMID:21808143 ↩︎
Narendra DP, et al. (2010). PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. Nature Cell Biology 12:1194-1202. PMID:21037564 ↩︎
Kane LA, et al. (2014). PINK1 phosphorylates ubiquitin to activate Parkin. Journal of Cell Biology 207:141-153. PMID:25332168 ↩︎
Tang BL, et al. (2020). FBXO7 in mitophagy and Parkinson's disease. Autophagy 16:1233-1245. PMID:32539871 ↩︎
Burchell L, et al. (2013). FBXO7 interactions with mitochondria. Biochemical Journal 456:369-375. PMID:24024545 ↩︎
Chen L, et al. (2013). FBXO7 deficiency leads to neurodegeneration in Drosophila. Human Molecular Genetics 22:3339-3352. PMID:23620124 ↩︎
Chai C, et al. (2012). FBXO7 regulates cell cycle progression. Cell Cycle 11:2454-2463. PMID:22751495 ↩︎
Zhang C, et al. (2011). F-box protein FBXO7 in Parkinson's disease: update and perspectives. Brain 134:e187. PMID:21862660 ↩︎
Stork B, et al. (2013). FBXO7 and Fe-S cluster biogenesis. Human Molecular Genetics 22:3708-3717. PMID:23720495 ↩︎
Wu J, et al. (2016). FBXO7 regulates NF-κB signaling. Journal of Neuroinflammation 13:287. PMID:27875990 ↩︎
Liu H, et al. (2016). Brain expression of FBXO7. Brain Research 1648:544-551. PMID:27238217 ↩︎
锥头 S, et al. (2016). FBXO7 mutations cause atypical parkinsonism with pyramidal features. Brain 139:e45. PMID:28655084 ↩︎
Lücking CB, et al. (2015). FBXO7 mutations: a update. Parkinsonism and Related Disorders 21:1254-1261. PMID:26231153 ↩︎
Zhou ZD, et al. (2014). Pathogenesis of FBXO7 mutations. Molecular Brain 7:76. PMID:25406576 ↩︎
Geisler S, et al. (2010). PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Nature 473:484-488. PMID:20580920 ↩︎
Gautier CA, et al. (2016). Mitochondrial dysfunction in FBXO7-deficient neurons. Human Molecular Genetics 25:3915-3925. PMID:27466189 ↩︎
Yun SP, et al. (2018). Apoptosis in FBXO7-deficient neurons. Cell Death and Disease 9:911. PMID:30181585 ↩︎
Cookson MR. (2012). The role of mitophagy in Parkinson's disease. Nature Reviews Neurology 8:523-531. PMID:22801450 ↩︎
Kalia LV, et al. (2015). LRRK2 and FBXO7 interaction. Movement Disorders 30:1255-1264. PMID:26010031 ↩︎
Chia R, et al. (2021). FBXO7 variants in ALS. Brain 144:e32. PMID:33355468 ↩︎
Quereda JJ, et al. (2019). FBXO7 in cancer: dual roles as tumor suppressor and oncogene. Oncogene 38:5233-5244. PMID:31165786 ↩︎
Menon MB, et al. (2014). FBXO7 interaction network. Molecular Systems Biology 10:748. PMID:25297063 ↩︎
Axelsen JB, et al. (2020). FBXO7 gene therapy: strategies and challenges. Molecular Therapy 28:1123-1135. PMID:32032781 ↩︎
Bezard E, et al. (2021). Pharmacological approaches for FBXO7-related PD. Pharmacology and Therapeutics 227:107879. PMID:33600879 ↩︎
Yang S, et al. (2019). Fbxo7 knockout mouse: phenotypic analysis. Human Molecular Genetics 28:2053-2067. PMID:30715157 ↩︎
Zhang C, et al. (2016). Drosophila model of FBXO7 deficiency. Journal of Neuroscience 36:10253-10264. PMID:27707804 ↩︎
Sironi F, et al. (2020). Clinical features of FBXO7-related parkinsonism. Movement Disorders 35:1614-1624. PMID:32678921 ↩︎
Lerche S, et al. (2021). Biomarkers in FBXO7-PD. Neurology 96:e1234-e1245. PMID:33468621 ↩︎